Global resistance surveillance: Ensuring antimalarial efficacy in the future

Current Opinion in Infectious Diseases

Volumn 22, Issue 6, 2009, Pages 593-600

  Guerin, Philippe J ^a   Bates, Sarah J ^a   Sibley, Carol H ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Community network; Malaria, population surveillance; Resistance; Treatment

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISIN;

ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; DRUG EFFICACY; GOOD CLINICAL PRACTICE; HEALTH PRACTITIONER; HUMAN; MALARIA; MEDICAL INFORMATION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; REVIEW; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ANTIMALARIALS; ARTEMISININS; DRUG COMBINATIONS; DRUG RESISTANCE; HUMANS; MALARIA; POPULATION SURVEILLANCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 70350557347     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328332c4a7     Document Type: Review

References (93)

1. WHO. World malaria report 2008 (report no. WHO/HTM/GMP/2008.1). Geneva, Switzerland: World Health Organization 2008.
2. WHO. Guidelines for the treatment of malaria (report no. WHO/HTM/MAL/2006.1108.). Geneva: World Health Organization 2006.
3. Dondorp A, Nosten F, Poravuth Y. Characterization of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-467.
4. Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in Western Cambodia. N Engl J Med 2008; 359:2619-2620
5. Greenhouse B, Slater M, Njamaa-Meya D, et al. Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis 2009; 199:758-765.
6. Baliraine F, Afrane Y, Amenya D, et al. High prevalence of asymptomatic Plasmodium falciparum infections in a highland area of Western Kenya: a cohort study. J Infect Dis 2009; 200:66-74.
7. Nacher M. Worms and malaria: blind men feeling the elephant? Parasitology 2008; 135:861-868.
8. Barnes KI, Watkins WM, White NJ. Antimalarial dosing regimens and drug resistance. Trends Parasitol 2008; 24:127-134.
9. White NJ, Stepniewska K, Barnes K, et al. Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol 2008; 24:159-163.
10. Basco LK. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. Geneva: World Health Organization; 2007.
11. Yang H, Yang Y, Yang P, et al. Monitoring Plasmodium falciparum chlor-oquine resistance in Yunnan Province, China, 1981-2006. Acta Tropica 2008; 108:44-49.
12. Carrara VI, Zwang J, Ashley EA, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS ONE 2009; 4:e4551
13. Pearce RJ, Pota H, Evehe MS, et al. Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med 2009;6:e1000055.
14. Laufer MK, Djimde AA, Plowe CV. Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am J Trop Med Hyg 2007; 77 (6 Suppl):160-169.
15. WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization; 2008
16. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009.
17. Guerra CA, Hay SI, Lucioparedes LS, et al. Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project. Malar J 2007; 6:1 7.
18. Hay SI, Guerra CA, Gething PW, et al. A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med 2009; 6:e48.
19. Hay SI, Smith DL, Snow RW. Measuring malaria endemicity from intense to interrupted transmission. Lancet Infect Dis 2008; 8:369-378.
20. Kitua AY, Corrah T, Herbst K, et al. Strengthening capacity, collaboration and quality of clinical research in Africa: EDCTP Networks of Excellence. Tanzan J Health Res 2009; 11:51-54.
21. Matee MI, Manyando C, Ndumbe PM, et al. European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership. BMC Public Health 2009; 9:249
22. MCTA. Malaria Clinical Trials Alliance. http://www.indepth-network.net/ mcta/mctaindex.htm.
23. Whitworth JAG, Kokwaro G, Kinyanjui S, et al. Strengthening capacity for health research in Africa. Lancet 2008; 372:1590-1593.
24. Schubert C. New initiative launched to support research in Africa. Nat Med 2009; 15:712
25. MCDC. Malaria Capacity Development Consortium. http://www.mcdconsor-tium. org/.
26. BMGF. Seattle: Bill & Melinda Gates Foundation; 2009; http://www.gates foundation.org/Grants-2009/Pages/World-Health-Organization- OPP51936. aspx
27. BMGF. WorldWide Antimalarial Resistance Network. Seattle: Bill & Melinda Gates Foundation; 2009. http://www.gatesfoundation.org/Grants-2009/ Pages/University-of-Oxford-OPP48807-01.aspx
28. RBM. Roll Back Malaria Partnership. http://www.rollbackmalaria.org/
29. Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience. Trop Med Int Health 2001; 6(11):891-898.
30. Sibley CH, Barnes KI, Watkins WM, Plowe CV. A network to monitor antimalarial drug resistance: a plan for moving forward. Trends Parasitol 2008; 24:43-48.
31. Newton PN, Hampton CY, Alter-Hall K, et al. Characterization of 'Yaa Chud' medicine on the Thailand-Myanmar border: selecting for drug-resistant malaria and threatening public health. Am J Trop Med Hyg 2008; 79:662-669.
32. Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa: a six country study. PLoS ONE 2008; 3:e2132.
33. Ashley EA, Stepniewska K, Lindegardh N, et al. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health 2007; 12:195-200.
34. Brown V, Guerin PJ, Legros D, et al. Research in complex humanitarian emergencies: the Medecins Sans Frontieres/Epicentre experience. PLoS Med 2008; 5:e89.
35. Guthmann JP, Checchi F, van den Broek I, et al. Assessing antimalarial efficacy in a time of change to artemisinin-based combination therapies: the role of Medecins Sans Frontieres. PLoS Med 2008; 5:e1 69.
36. Prugger C, Engl M, Ogwang M, et al. Malariological baseline survey and in vitro antimalarial drug resistance in Gulu district, Northern Uganda. Wien Klin Wochenschr 2008; 120 (19-20 Suppl 4):63-68.
37. D'Ortenzio E, Godineau N, Fontanet A, et al. Prolonged Plasmodium falciparum infection in immigrants, Paris. Emerg Infect Dis 2008; 14:323-326.
38. Behrens R, Carroll B, Smith V, Alexander N. Declining incidence of malaria imported into the UK from West Africa. Malar J 2008; 7:235.
39. Smith AD, Bradley DJ, Smith V, et al. Imported malaria and high risk groups: observational study using UK surveillance data 1987-2006. BMJ 2008; 337:a120.
40. Borrmann S, PetoT, Snow RW, et al. Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria. PLoS Med 2008; 5:e227.
41. Chotivanich K, Sattabongkot J, Choi YK, et al. Antimalarial drug susceptibility of Plasmodium vivax in the Republic of Korea. Am J Trop Med Hyg 2009; 80:902-904.
42. Co E-MA, Dennull RA, Reinbold DD, et al. Assessment of malaria in vitro drug combination screening and mixed strain infections using the malaria SYBR green I-based fluorescence assay. Antimicrob Agents Chemother 2009; 53:2557-2563.
43. Alifrangis M, Lusingu JP, MmbandoB, et al. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. Am J Trop Med Hyg 2009; 80:523-527.
44. Anderson T. Mapping the spread of malaria drug resistance. PLoS Med 2009; 6:e1000054.
45. Bacon DJ, McCollum AM, Griffing SM, et al. Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria. Antimicrob Agents Chemother 2009; 53:2042-2051.
46. Djimde A, Fofana B, Sagara I, et al. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg 2008; 78:455-461.
47. Happi CT, Gbotosho GO, Folarin OA, et al. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and game-tocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother 2009; 53:888-895.
48. Picot S, Olliaro P, de Monbrison F, et al. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J 2009; 8:89.
49. Okell LC, Drakeley CJ, Ghani AC, et al. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J 2008; 7:125.
50. Barnes KI, Little F, Mabuza A, et al. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine- pyrimethamine resistance in falciparum malaria. J Infect Dis 2008; 197:1605-1613.
51. Ghani AC, Sutherland CJ, Riley EM, et al. Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends. PLoS ONE 2009; 4:e4383.
52. Teklehaimanot HD, Teklehaimanot A, Kiszewski A, et al. Malaria in Sao Tome and Principe: on the brink of elimination after three years of effective antimalarial measures. Am J Trop Med Hyg 2009; 80:133-140.
53. Klinkenberg E, McCall P, Wilson MD, et al. Impact of urban agriculture on malaria vectors in Accra. Malar J 2008; 7:151.
54. Dondorp AM, Lee SJ, Faiz MA, et al. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis 2008; 47:151-157.
55. Kleinschmidt I, Schwabe C, Benavente L, et al. Marked increase in child survival after four years of intensive malaria control. Am J Trop Med Hyg 2009; 80:882-888.
56. Okiro EA, Hay SI, Gikandi PW, et al. The decline in paediatric malaria admissions on the coast of Kenya. Malar J 2007; 6:151.
57. Rodrigues A, Schellenberg JA, Kofoed P-E, et al. Changing pattern of malaria in Bissau, Guinea Bissau. Trop Med Int Health 2008; 13:410-417.
58. Cox J, Hay SI, Abeku TA, et al. The uncertain burden of Plasmodium falciparum epidemics in Africa. Trends Parasitol 2007; 23:142-148.
59. Korenromp EL, Williams BG, Gouws E, et al. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis 2003; 3:349-358.
60. Martin SK, Rajasekariah G-H, Awinda G, et al. Unified parasite lactate dehydrogenase and histidine-rich protein ELISA for quantification of Plasmodium falciparum. Am J Trop Med Hyg 2009; 80:516-522.
61. Sutherland CJ, Hallett R. Detecting malaria parasites outside the blood. J Infect Dis 2009; 199:1561-1563.
62. Nwakanma DC, Gomez-Escobar N, WaltherM, et al. Quantitative detection of Plasmodium falciparum DNA in saliva, blood, and urine. J Infect Dis 2009; 199:1567-1574.
63. Mens PF, van Amerongen A, Sawa P, et al. Molecular diagnosis of malaria in the field: development of a novel 1-step nucleic acid lateral flow immunoassay for the detection of all 4 human Plasmodium spp. and its evaluation in Mbita, Kenya. Diagn Microbiol Infect Dis 2008; 61:421-427.
64. Gatton ML, Cheng Q. Can estimates of antimalarial efficacy from field studies be improved? Trends Parasitol 2008; 24:68-73.
65. Pongtavornpinyo W, Yeung S, Hastings IM, et al. Spread of antimalarial drug resistance: mathematical model with implications for ACT drug policies. Malar J 2008; 7:229.
66. Breslauer DN, Maamari RN, Switz NA, et al. Mobile phone based clinical microscopy for global health applications. PLoS ONE 2009; 4:e6320.
67. Newman DM, Heptinstall J, Matelon RJ, et al. A magneto-optic route toward the in vivo diagnosis of malaria: preliminary results and preclinical trial data. Biophys J 2008; 95:994-1000.
68. Brownstein JS, Freifeld CC, Reis BY, Mandl KD. Surveillance Sans Frontieres: internet-based emerging infectious disease intelligence and the HealthMap project. PLoS Med 2008; 5:e151.
69. D'Acremont V, Lengeler C, Mshinda H, et al. Time to move from presumptive malaria treatment to laboratory-confirmed diagnosis and treatment in African children with fever. PLoS Med 2009; 6:e252.
70. Nicastri E, Bevilacqua N, Schepisi MS, et al. Accuracy of malaria diagnosis by microscopy, rapid diagnostic test, and PCR methods and evidence of antimalarial overprescription in non-severe febrile patients in two Tanzanian hospitals. Am J Trop Med Hyg 2009; 80:712-717
71. WHO Malaria Rapid Diagnostic Test Performance: Results of WHO Product Testing of Malaria RDTs-Round 1 Geneva: World Health Organization 2008http://apps.who.int/tdr/publications/tdr-research-publications/ rdt-performance/pdf/executive-summary-malaria-RDTs.pdf
72. Juliano J, Taylor S, Meshnick S. Polymerase chain reaction adjustment in antimalarial trials: molecular malarkey? J Infect Dis 2009; 200:5-7.
73. Juliano JJ, Ariey F, Sem R, et al. Misclassification of drug failure in Plasmodium falciparum clinical trials in southeast Asia. J Infect Dis 2009; 200:624-628
74. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 2009; 22:508-534.
75. Roper C, Pearce R, Nair S, et al. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004; 305:1124.
76. Noranate N, Durand R, Tall A, et al. Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS ONE 2007; 2:e139.
77. Jeffares DC. Genome variation and evolution of the malaria parasite Plas-modium falciparum. Nat Genet 2007; 39:120-125.
78. Mu J, Awadalla P, Duan J, et al. Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nat Genet 2007; 39:126-130.
79. Volkman SK. A genome-wide map of diversity in Plasmodium falciparum. Nat Genet 2007; 39:113-119.
80. Dia I, Konate L, Samb B, et al. Bionomics of malaria vectors and relationship with malaria transmission and epidemiology in three physiographic zones in the Senegal River Basin. Acta Tropica 2008; 105:145-153.
81. Drakeley C, Cook J. Potential contribution of sero-epidemiological analysis for monitoring malaria control and elimination: historical and current perspectives. Adv Parasitol 2009; 69:299-352.
82. Stewart L, Gosling R, Griffin J, et al. Rapid assessment of malaria transmission using age-specific sero-conversion rates. PLoS ONE 2009; 4:e6083.
83. Snow RW, Trape JF, Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol 2001; 17:593-597.
84. Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 2001; 64 (1-2 Suppl):12-17.
85. Trape JF, Pison G, Preziosi MP, et al. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III 1998; 321:689-697
86. INDEPTH. International Network of field sites with continuous Demographic Evaluation of Populations and Their Health. http://www.indepth-network.org/.
87. Kleppner D, Sharp PA. Research Data in the Digital Age. Science 2009; 325:368.
88. Chowell G, Munayco C, Escalante A, McKenzie FE. The spatial and temporal patterns of falciparum and vivax malaria in Peru: 1994-2006. Malar J 2009; 8:142.
89. Fegan GW, Noor AM, Akhwale WS, et al. Effect of expanded insecticide-treated bednet coverage on child survival in rural Kenya: a longitudinal study. Lancet 2007; 370:1035-1039.
90. Tahar R, Ringwald P, Basco LK. Molecular epidemiology of malaria in Cameroon. XXVIII. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum and sequence analysisofthe P.falciparum ATPase 6 gene. Am J Trop Med Hyg 2009; 81:13-18.
91. Boni MF, Smith DL, Laxminarayan R. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci U S A 2008; 105:14216-14221.
92. Guerra CA, Gikandi PW, Tatem AJ, et al. The limits and intensity of Plas-modium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 2008; 5:e38
93. IRI. International Research Institute for Climate and Society. http://portal. iri.columbia.edu/portal/server.pt